Production, market and benchmarking of Carnitine in China

Production, market and benchmarking of Carnitine in China
  • Report price : $ 10 000
  • Publication date : September 2008
  • Length : 110 pages

Get this Report Now !

Production, market and benchmarking of Carnitine in China

L-Carnitine, a natural and water soluble nutrient that can be produced by human body and also can be obtained from muscles, is an indispensable factor in the metabolism of fat and has many essential functions in human body.

These years, the role of Chinese L-Carnitine industry in the world has become more and more important. Although L-Carnitine has been discovered for over a century and has developed quite well in Switzerland, Italy, US and Japan, the production and industrial application of L-Carnitine in China just began 10~15 years ago. However, the L-Carnitine industry develops rapidly in China. At the moment, China’s L-Carnitine is competitive both at home and aboard thanks to its low price and good quality. 12 Chinese producers are active in production of L-Carnitine currently. Their total output of L-Carnitine in 2007 reached 1,408 tonnes, 34.94% of which was exported. And only small quantity of L-Carnitine is imported.

What will the role of China's L-Carnitine industry be in the global market? Will the export volume grow larger in the future? This report will answer these questions.

Because of the Beijing Olympic Games and the rising prices of some major raw materials, the price of L-Carnitine has been growing since the end of 2007 or early 2008, and it has been 20%~40% higher than that in the past 3 years. How does it influence domestic L-Carnitine production and the export? Can domestic L-Carnitine producers earn considerable profit under the current situation? CCM will give a detailed analysis in this report.

Driven by the huge profits and positive market prospects, many Chinese L-Carnitine manufacturers expand their capacities. It is forecasted that production capacity of L-Carnitine in China will have a sharp rise in the next few years. The competition between L-Carnitine manufacturers in China will be increasingly apparent. Moreover, with the development of oversea producers, the competitions among countries will grow increasingly intense. Compared with some internationally well-known L-Carnitine producers such as Lonza, are there any other competitive advantages in major domestic L-Carnitine producers apart from low production cost? Can they still earn satisfying profit when facing the international L-Carnitine producing giants?

L-Carnitine is mainly used in health food and feed in China. As China is a country with huge potential market for health food and feed and more and more Chinese people realize the importance of health food, the consumption of L-Carnitine will be even larger in China. Are there any other potential large consumption fields of L-Carnitine in China? What is the future of L-Carnitine production in China? This report will also reveal the current situations of L-Carnitine application and demand in China.

RELATED REPORTS

The Future of RNAi Therapeutics: Drug Pipelines and Prospects

The Future of RNAi Therapeutics: Drug Pipelines and Prospects

  • $ 3 835
  • September 2008
  • 253 pages

RNA interference continues to offer significant promise for a host of therapeutic treatments. Potentially any disease-causing gene, cell type or tissue can be targeted with RNAi, including those not ‘druggable’ with small molecules or protein-based therapies. Pharma companies are increasingly in ...

Industries : Pharmaceutical

The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

The CNS Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

  • $ 3 835
  • September 2008
  • 231 pages

The CNS disorders market is one of the largest and fastest growing markets in the pharmaceutical industry. Reimbursement terms continue to be favorable within the area, despite the relatively high risks associated with product development. This is largely due to significant levels of unmet medical n ...

Industries : Pharmaceutical

Mitsubishi Tanabe Pharma Corporation

Mitsubishi Tanabe Pharma Corporation

  • $ 125
  • September 2008
  • 24 pages

Datamonitor's Mitsubishi Tanabe Pharma Corporation - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue li ...

Industries : Pharmaceutical

Universal Health Services, Inc.

Universal Health Services, Inc.

  • $ 125
  • September 2008
  • 23 pages

Datamonitor's Universal Health Services, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines a ...

Industries : Pharmaceutical

CV Therapeutics, Inc.

CV Therapeutics, Inc.

  • $ 125
  • September 2008
  • 24 pages

Datamonitor's CV Therapeutics, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the company’s key business structure and operations, history and products, and provides summary analysis of its key revenue lines and strateg ...

Industries : Pharmaceutical

Medical Nanotechnology Markets

Medical Nanotechnology Markets

  • $ 3 400
  • September 2008

Nanotechnology has reached critical mass. Nowhere is this more evident than in medicine. Rising medical costs, demands for less-invasive procedures and pressures for immediate feedback of medical conditions, all point to nanotechnology as offering a new approach in healthcare. According to U.S. Nati ...

Industries : Pharmaceutical

Osteoporosis & Bone Metabolism Disorders 2008-2023

Osteoporosis & Bone Metabolism Disorders 2008-2023

  • $ 2 501
  • August 2008

In 2007, the world market for bone metabolism disorder pharmaceuticals generated sales of over $10bn - how much of this market have you captured?The majority of this market consists of the fast-expanding osteoporosis segment, a disease with high incidence and under-treatment at present. The bone met ...

Industries : Pharmaceutical

Pfizer - Market Outlook for a Global Leader, 2008-2013

Pfizer - Market Outlook for a Global Leader, 2008-2013

  • $ 2 501
  • January 2008

Pfizer is the world's largest and most profitable pharmaceutical company. Its pharmaceutical division generates sales of $44671m in 2007. Pfizer is recognised as being one of the strongest performing pharmaceutical companies in terms of sales, revenue growth, acquisitions, breadth of portfolio, prod ...

Industries : Pharmaceutical

Therapeutic Monoclonal Antibodies Report 2008-2023

Therapeutic Monoclonal Antibodies Report 2008-2023

  • $ 2 501
  • July 2008

This brand new report investigates the global market for therapeutic monoclonal antibodies. While the pharmaceutical industry as a whole is suffering from single digit growth, thinner pipelines than before and pressure from an ever-aggressive generics industry, the segment of monoclonal antibodies t ...

Industries : Pharmaceutical

Global Clinical Trial Business Report and Analysis 2008-2018

Global Clinical Trial Business Report and Analysis 2008-2018

  • $ 2 501
  • October 2008

The global clinical trials business is worth an estimated $50bn in 2008, with a growth of rate of 10%. The market will show considerable growth in the future, as this visiongain report, Global Clinical Trial Business 2008-2018, explains in detail. In recent years, the nature of clinical trials has c ...

Industries : Pharmaceutical

24/7 Customer Service

Contact Clare now !

Related industries

reportlinker.com © Copyright 2009. All rights reserved

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.